HeeJin Cheon1,2,3, Karolina H Dziewulska1,4, Katharine B Moosic1,4, Kristine C Olson1, Alejandro A Gru4, David J Feith1, Thomas P Loughran5. 1. Department of Medicine, Division of Hematology & Oncology, University of Virginia Cancer Center, PO Box 800334, Charlottesville, VA, 22908-0334, USA. 2. Department of Biochemistry and Molecular Genetics, Charlottesville, VA, 22908, USA. 3. Medical Scientist Training Program, Charlottesville, VA, 22908, USA. 4. Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA. 5. Department of Medicine, Division of Hematology & Oncology, University of Virginia Cancer Center, PO Box 800334, Charlottesville, VA, 22908-0334, USA. TL7CS@hscmail.mcc.virginia.edu.
Abstract
PURPOSE OF REVIEW: The past decade in LGL leukemia research has seen increased pairing of clinical data with molecular markers, shedding new insights on LGL leukemia pathogenesis and heterogeneity. This review summarizes the current standard of care of LGL leukemia, updates from clinical trials, and our congruent improved understanding of LGL pathogenesis. RECENT FINDINGS: Various clinical reports have identified associations between stem, bone marrow, and solid organ transplants and incidence of LGL leukemia. There is also a potential for underdiagnosis of LGL leukemia within the rheumatoid arthritis patient population, emphasizing our need for continued study. Preliminary results from the BNZ-1 clinical trial, which targets IL-15 along with IL-2 and IL-9 signaling pathways, show some evidence of clinical response. With advances in our understanding of LGL pathogenesis from both the bench and the clinic, exciting avenues for investigations lie ahead for LGL leukemia.
PURPOSE OF REVIEW: The past decade in LGL leukemia research has seen increased pairing of clinical data with molecular markers, shedding new insights on LGL leukemia pathogenesis and heterogeneity. This review summarizes the current standard of care of LGL leukemia, updates from clinical trials, and our congruent improved understanding of LGL pathogenesis. RECENT FINDINGS: Various clinical reports have identified associations between stem, bone marrow, and solid organ transplants and incidence of LGL leukemia. There is also a potential for underdiagnosis of LGL leukemia within the rheumatoid arthritispatient population, emphasizing our need for continued study. Preliminary results from the BNZ-1 clinical trial, which targets IL-15 along with IL-2 and IL-9 signaling pathways, show some evidence of clinical response. With advances in our understanding of LGL pathogenesis from both the bench and the clinic, exciting avenues for investigations lie ahead for LGL leukemia.
Entities:
Keywords:
Autoimmunity; BNZ-1; Large granular lymphocyte leukemia; Organ transplant; STAT3
Authors: Michael J Clemente; Marcin W Wlodarski; Hideki Makishima; Aaron D Viny; Isabell Bretschneider; Mohammad Shaik; Nelli Bejanyan; Alan E Lichtin; Eric D Hsi; Eric D His; Ronald L Paquette; Thomas P Loughran; Jaroslaw P Maciejewski Journal: Blood Date: 2011-08-24 Impact factor: 22.113
Authors: Deborah L Hodge; Jun Yang; Matthew D Buschman; Paul M Schaughency; Hong Dang; William Bere; Yili Yang; Ram Savan; Jeff J Subleski; Xiao-Ming Yin; Thomas P Loughran; Howard A Young Journal: Cancer Res Date: 2009-04-14 Impact factor: 12.701
Authors: Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Koskela; Francis Leblanc; Kwok Peng Ng; Thomas Olson; Bartlomiej Przychodzen; Manuel Afable; Ines Gomez-Segui; Kathryn Guinta; Lisa Durkin; Eric D Hsi; Kathy McGraw; Dan Zhang; Marcin W Wlodarski; Kimmo Porkka; Mikkael A Sekeres; Alan List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski Journal: Blood Date: 2012-08-02 Impact factor: 22.113
Authors: Martine J Kallemeijn; Dick de Ridder; Joyce Schilperoord-Vermeulen; Michèle Y van der Klift; Yorick Sandberg; Jacques J M van Dongen; Anton W Langerak Journal: PLoS One Date: 2017-04-13 Impact factor: 3.240
Authors: Weiling Li; Lei Yang; Robert S Harris; Lin Lin; Thomas L Olson; Cait E Hamele; David J Feith; Thomas P Loughran; Mary Poss Journal: BMC Med Genomics Date: 2019-06-17 Impact factor: 3.063
Authors: HeeJin Cheon; Jeffrey C Xing; Katharine B Moosic; Johnson Ung; Vivian W Chan; David S Chung; Mariella F Toro; Omar Elghawy; John S Wang; Cait E Hamele; Ross C Hardison; Thomas L Olson; Su-Fern Tan; David J Feith; Aakrosh Ratan; Thomas P Loughran Journal: Blood Date: 2022-05-19 Impact factor: 25.476
Authors: Katharine B Moosic; Kusuma Ananth; Felipe Andrade; David J Feith; Erika Darrah; Thomas P Loughran Journal: Front Oncol Date: 2022-05-13 Impact factor: 5.738
Authors: Natali Pflug; Annika Littauer; David Beverungen; Aleksandra Sretenovic; Linus Wahnschaffe; Till Braun; Annika Dechow; Dennis Jungherz; Moritz Otte; Astrid Monecke; Enrica Bach; Georg-Nikolaus Franke; Sebastian Schwind; Madlen Jentzsch; Uwe Platzbecker; Marco Herling; Vladan Vucinic Journal: Front Oncol Date: 2022-01-05 Impact factor: 6.244